- Current report filing (8-K)
04 Août 2009 - 10:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
August 4, 2009
ALLOS
THERAPEUTICS, INC.
(Exact name of registrant
as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
|
|
|
|
11080
CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrants telephone
number, including area code:
(303) 426-6262
Not
applicable
(Former name or former
address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 2 Financial
Information
Item 2.02 Results
of Operations and Financial Condition.
On August 4,
2009, Allos Therapeutics, Inc., a Delaware corporation, issued a press
release reporting financial results for the second quarter of 2009. The
press release is attached hereto as Exhibit 99.1, which is furnished under
Item 2.02 of this report and shall not be deemed to be filed for purposes of Section 18
of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange
Act, regardless of any general incorporation language in such filing.
Section 9 Financial
Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1
|
|
Press Release, dated
August 4, 2009, entitled Allos
Therapeutics Reports Second Quarter 2009 Financial Results.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: August 4, 2009
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ David C. Clark
|
|
|
David C. Clark
|
|
Its:
|
Vice President, Finance
and Treasurer
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated
August 4, 2009, entitled Allos
Therapeutics Reports Second Quarter 2009 Financial Results.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024